Incidence of extramedullary disease in patients with acute promyelocytic leukemia: A single-institution experience

Arturo Vega-Ruiz, Stefan Faderl, Zeev Estrov, Sherry Pierce, Jorge Cortes, Hagop Kantarjian, Farhad Ravandi

Research output: Contribution to journalArticle

Abstract

Using current treatment regimens, over 90% of patients with acute promyelocytic leukemia will achieve complete remission (CR). However, approximately 30% of these patients will relapse, including a small proportion who will develop extramedullary disease (EMD). In this study, we investigated the incidence of EMD in 263 patients with APL who were treated at our institution from January 1990 to May 2008. With a median follow-up of 31 months (range 2 days-203 months), 8 (3%) patients developed EMD. The most commonly affected site was the central nervous system (n = 7). Before developing EMD, one patient had achieved CR with a chemotherapy-only regimen, six patients had achieved CR with all-trans-retinoic acid (ATRA)-based regimens, and one patient had achieved CR with an ATRA plus arsenic trioxide (ATO)-based regimen. The EMD conferred a poor prognosis; five patients died within 4 months of developing EMD. The molecular status did not predict EMD; four patients had a negative PCR for the PML-RARA transcripts prior to relapse with EMD. In conclusion, the incidence of EMD is low. We were unable to identify any specific factors that could predict the development of EMD.

Original languageEnglish (US)
Pages (from-to)489-496
Number of pages8
JournalInternational Journal of Hematology
Volume89
Issue number4
DOIs
StatePublished - May 1 2009
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Incidence
Tretinoin
Recurrence
Central Nervous System
Drug Therapy
Polymerase Chain Reaction

Keywords

  • Acute promyelocytic leukemia
  • All-trans-retinoic acid
  • Extramedullary disease
  • Trioxide arsenic

ASJC Scopus subject areas

  • Hematology

Cite this

Incidence of extramedullary disease in patients with acute promyelocytic leukemia : A single-institution experience. / Vega-Ruiz, Arturo; Faderl, Stefan; Estrov, Zeev; Pierce, Sherry; Cortes, Jorge; Kantarjian, Hagop; Ravandi, Farhad.

In: International Journal of Hematology, Vol. 89, No. 4, 01.05.2009, p. 489-496.

Research output: Contribution to journalArticle

Vega-Ruiz, Arturo ; Faderl, Stefan ; Estrov, Zeev ; Pierce, Sherry ; Cortes, Jorge ; Kantarjian, Hagop ; Ravandi, Farhad. / Incidence of extramedullary disease in patients with acute promyelocytic leukemia : A single-institution experience. In: International Journal of Hematology. 2009 ; Vol. 89, No. 4. pp. 489-496.
@article{0237c94f6dc04cc1aef63fb95c0169e3,
title = "Incidence of extramedullary disease in patients with acute promyelocytic leukemia: A single-institution experience",
abstract = "Using current treatment regimens, over 90{\%} of patients with acute promyelocytic leukemia will achieve complete remission (CR). However, approximately 30{\%} of these patients will relapse, including a small proportion who will develop extramedullary disease (EMD). In this study, we investigated the incidence of EMD in 263 patients with APL who were treated at our institution from January 1990 to May 2008. With a median follow-up of 31 months (range 2 days-203 months), 8 (3{\%}) patients developed EMD. The most commonly affected site was the central nervous system (n = 7). Before developing EMD, one patient had achieved CR with a chemotherapy-only regimen, six patients had achieved CR with all-trans-retinoic acid (ATRA)-based regimens, and one patient had achieved CR with an ATRA plus arsenic trioxide (ATO)-based regimen. The EMD conferred a poor prognosis; five patients died within 4 months of developing EMD. The molecular status did not predict EMD; four patients had a negative PCR for the PML-RARA transcripts prior to relapse with EMD. In conclusion, the incidence of EMD is low. We were unable to identify any specific factors that could predict the development of EMD.",
keywords = "Acute promyelocytic leukemia, All-trans-retinoic acid, Extramedullary disease, Trioxide arsenic",
author = "Arturo Vega-Ruiz and Stefan Faderl and Zeev Estrov and Sherry Pierce and Jorge Cortes and Hagop Kantarjian and Farhad Ravandi",
year = "2009",
month = "5",
day = "1",
doi = "10.1007/s12185-009-0291-8",
language = "English (US)",
volume = "89",
pages = "489--496",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Incidence of extramedullary disease in patients with acute promyelocytic leukemia

T2 - A single-institution experience

AU - Vega-Ruiz, Arturo

AU - Faderl, Stefan

AU - Estrov, Zeev

AU - Pierce, Sherry

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Ravandi, Farhad

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Using current treatment regimens, over 90% of patients with acute promyelocytic leukemia will achieve complete remission (CR). However, approximately 30% of these patients will relapse, including a small proportion who will develop extramedullary disease (EMD). In this study, we investigated the incidence of EMD in 263 patients with APL who were treated at our institution from January 1990 to May 2008. With a median follow-up of 31 months (range 2 days-203 months), 8 (3%) patients developed EMD. The most commonly affected site was the central nervous system (n = 7). Before developing EMD, one patient had achieved CR with a chemotherapy-only regimen, six patients had achieved CR with all-trans-retinoic acid (ATRA)-based regimens, and one patient had achieved CR with an ATRA plus arsenic trioxide (ATO)-based regimen. The EMD conferred a poor prognosis; five patients died within 4 months of developing EMD. The molecular status did not predict EMD; four patients had a negative PCR for the PML-RARA transcripts prior to relapse with EMD. In conclusion, the incidence of EMD is low. We were unable to identify any specific factors that could predict the development of EMD.

AB - Using current treatment regimens, over 90% of patients with acute promyelocytic leukemia will achieve complete remission (CR). However, approximately 30% of these patients will relapse, including a small proportion who will develop extramedullary disease (EMD). In this study, we investigated the incidence of EMD in 263 patients with APL who were treated at our institution from January 1990 to May 2008. With a median follow-up of 31 months (range 2 days-203 months), 8 (3%) patients developed EMD. The most commonly affected site was the central nervous system (n = 7). Before developing EMD, one patient had achieved CR with a chemotherapy-only regimen, six patients had achieved CR with all-trans-retinoic acid (ATRA)-based regimens, and one patient had achieved CR with an ATRA plus arsenic trioxide (ATO)-based regimen. The EMD conferred a poor prognosis; five patients died within 4 months of developing EMD. The molecular status did not predict EMD; four patients had a negative PCR for the PML-RARA transcripts prior to relapse with EMD. In conclusion, the incidence of EMD is low. We were unable to identify any specific factors that could predict the development of EMD.

KW - Acute promyelocytic leukemia

KW - All-trans-retinoic acid

KW - Extramedullary disease

KW - Trioxide arsenic

UR - http://www.scopus.com/inward/record.url?scp=67449143392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449143392&partnerID=8YFLogxK

U2 - 10.1007/s12185-009-0291-8

DO - 10.1007/s12185-009-0291-8

M3 - Article

C2 - 19340529

AN - SCOPUS:67449143392

VL - 89

SP - 489

EP - 496

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 4

ER -